Single‑dose intra‑arterial neoadjuvant chemotherapy while waiting for radical hysterectomy for stage IB‑IIB cervical cancer

Yoshino,Kiyoshi; Hosoi,Ayako; Osuga,Keigo; Enomoto,Takayuki; Ueda,Yutaka; Sawada,Kenjiro; Mabuchi,Seiji; Kobayashi,Eiji; Matsuo,Koji; Kimura,Tadashi

doi:10.3892/mco.2016.846

June-2016 Volume 4 Issue 6

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

June-2016 Volume 4 Issue 6

Full Size Image

Article

Single‑dose intra‑arterial neoadjuvant chemotherapy while waiting for radical hysterectomy for stage IB‑IIB cervical cancer

Authors:
- Kiyoshi Yoshino
- Ayako Hosoi
- Keigo Osuga
- Takayuki Enomoto
- Yutaka Ueda
- Kenjiro Sawada
- Seiji Mabuchi
- Eiji Kobayashi
- Koji Matsuo
- Tadashi Kimura
View Affiliations / Copyright

Affiliations: Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Suita, Osaka 565‑0871, Japan, Department of Diagnostic and Interventional Radiology, Osaka University Graduate School of Medicine, Suita, Osaka 565‑0871, Japan, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA 90089, USA
Pages: 1068-1072
|
Published online on: April 4, 2016

https://doi.org/10.3892/mco.2016.846
Expand metrics +

Abstract

Extended wait time prior to initial surgery may increase patients' anxiety. Therefore, patients may opt to receive other available treatments to inhibit tumor growth until surgery. This retrospective study describes our experience with single‑dose intra‑arterial neoadjuvant chemotherapy (IANAC) to more effectively utilize the wait time prior to radical hysterectomy. A total of 12 patients with International Federation of Gynecology and Obstetrics stage IB1‑IIB cervical cancer were treated with single‑dose IANAC prior to radical hysterectomy. Cisplatin and paclitaxel were administered intra‑arterially or intravenously, respectively. the surgical outcome, prognosis and factors affecting disease recurrence were compared between these 12 patients and 57 patients in a primary surgery alone (PS) control group. As regards surgical outcome, there were no significant differences between the two groups. During the postoperative follow‑up period (median, 41 months), disease recurrence was observed in 5̸12 (41.6%) IANAC cases and in 22̸57 (38.5%) PS cases (median follow‑up, 54 months). There was no significant difference in disease‑free survival (DFS) or 3‑year survival rates between IANAC and PS (91.6 vs. 71.9%, respectively). The multivariate analysis demonstrated that wait time duration (≥45 vs. <45 days) and the use of IANAC did not affect DFS. Only tumor histology (squamous vs. non‑squamous) was found to be an independent prognostic factor for DFS (hazard ratio = 0.35, 95% confidence inerval: 0.145‑0.8967, P=0.0292). In addition, distal recurrence was statistically more frequent in the IANAC group compared with that in the PS group (P=0.0405). Therefore, single‑cycle IANAC should not be performed without careful consideration.

View Figures

View References

1	Richards MA, Westcombe AM, Love SB, Littlejohns P and Ramirez AJ: Influence of delay on survival in patients with breast cancer: A systematic review. Lancet. 353:1119–1126. 1999. View Article : Google Scholar : PubMed/NCBI
2	Elit LM, O'Leary EM, Pond GR and Seow HY: Impact of wait times on survival for women with uterine cancer. J Clin Oncol. 32:27–33. 2014. View Article : Google Scholar : PubMed/NCBI
3	Sugiyama T, Nishida T, Hasuo Y, Fujiyoshi K and Yakushiji M: Neoadjuvant intraarterial chemotherapy followed by radical hysterectomy and/or radiotherapy for locally advanced cervical cancer. Gynecol Oncol. 69:130–136. 1998. View Article : Google Scholar : PubMed/NCBI
4	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D and Verweij J: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
5	Yamakawa Y, Fujimura M, Hidaka T, Hori S and Saito S: Neoadjuvant intraarterial infusion chemotherapy in patients with stage IB2-IIIB cervical cancer. Gynecol Oncol. 77:264–270. 2000. View Article : Google Scholar : PubMed/NCBI
6	Aoki Y, Sato T, Watanabe M, Sasaki M, Tsuneki I and Tanaka K: Neoadjuvant chemotherapy using low-dose consecutive intraarterial infusions of cisplatin combined with 5-fluorouracil for locally advanced cervical adenocarcinoma. Gynecol Oncol. 81:496–499. 2001. View Article : Google Scholar : PubMed/NCBI
7	Motoyama S, Hamana S, Ku Y, Laoag-Fernandez JB, Deguchi M, Yoshida S, Tominaga M, Iwasaki T, Ohara N and Maruo T: Neoadjuvant high-dose intraarterial infusion chemotherapy under percutaneous pelvic perfusion with extracorporeal chemofiltration in patients with stages IIIa-IVa cervical cancer. Gynecol Oncol. 95:576–582. 2004. View Article : Google Scholar : PubMed/NCBI
8	Terai Y, Kanemura M, Sasaki H, Tsunetoh S, Tanaka Y, Yamashita Y, Yamamoto K, Narabayashi I and Ohmichi M: Long-term follow-up of neoadjuvant intraarterial chemotherapy using an original four-lumen double-balloon (4L-DB) catheter for locally advanced uterine cervical cancer. Int J Clin Oncol. 14:56–62. 2009. View Article : Google Scholar : PubMed/NCBI
9	Kaku S, Takahashi K, Murakami Y, Wakinoue S, Nakagawa T, Shimizu Y, Kita N, Noda Y and Murakami T: Neoadjuvant intraarterial chemotherapy for stage IIB-IIIB cervical cancer in Japanese women. Exp Ther Med. 1:651–655. 2010. View Article : Google Scholar : PubMed/NCBI
10	Bell J, Brady MF, Young RC, Lage J, Walker JL, Look KY, Rose GS and Spirtos NM: Gynecologic Oncology Group: Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol. 102:432–439. 2006. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Single‑dose intra‑arterial neoadjuvant chemotherapy while waiting for radical hysterectomy for stage IB‑IIB cervical cancer

This article is mentioned in:

Abstract

Figure 1

Figure 2

Related Articles